Skip to content

The Effect of Total Intravenous Anesthesia with Cyprofol and Propofol on Postoperative Recovery Quality in Patients Undergoing Daytime Laparoscopic Cholecystectomy

The Effect of Total Intravenous Anesthesia with Cyprofol and Propofol on Postoperative Recovery Quality in Patients Undergoing Daytime Laparoscopic Cholecystectomy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097514
Enrollment
Unknown
Registered
2025-02-20
Start date
2025-02-21
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic cholecystectomy

Interventions

Cyprofol group:During anesthesia induction, a loading dose of Cyprofol is administered at 0.5–0.6 mg/kg, followed by a continuous intravenous infusion of Cyprofol (maintaining BIS in the range of 40-6
Propofol group:During anesthesia induction, a loading dose of Propofol is administered at 1.5–2.5 mg/kg, followed by a continuous intravenous infusion of Propofol (maintaining BIS in the range of 40-6

Sponsors

First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-65 years; 2) Daytime surgery; 3) Scheduled to undergo laparoscopic cholecystectomy under general anesthesia; 4) Agree to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Refusal to participate in this study; 2) ASA III. level or above; 3) BMI29.9kg/m^2; 4) History of chronic analgesic or sedative drug use including benzodiazepines, alcohol abuse, allergy to cyclopofol or propofol; 5) history of insomnia; 6) MMSE score of severe cognitive impairment before operation=180mmHg; 10) Surgery within the past 3 months; Participation in other research studies within the past 30 days; 11) Patients who have taken hormones or other immunosuppressive drugs for more than 10 days in the past 6 months or have a history of adrenal suppression or immune system disorders.

Design outcomes

Primary

MeasureTime frame
Quality of Recovery-15, QoR-15;

Secondary

MeasureTime frame
Postoperative hospital complications;Response time to verbal commands and extubation time;PACU stay time;Patient self-reported pain, anesthesia comfort, and satisfaction.;

Countries

China

Contacts

Public ContactYao Lu

First Affiliated Hospital of Anhui Medical University

luyao@ahmu.edu.cn+86 189 5656 4060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026